Skip to main content
Journal ArticleOPEN ACCESS

Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy

  • Ravasio R
  • Antonelli S
  • Rogai V
  • et al.
Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish (2018) 2018 228424031879095
DOI: 10.1177/2284240318790951
N/ACitations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Biological disease-modifying antirheumatic drugs are recommended for use particularly in rheumatoid arthritis patients who had an inadequate response to methotrexate but they are costly. In this ar...

Cite

CITATION STYLE

APA

Ravasio, R., Antonelli, S., Rogai, V., Fakhouri, W., Capron, J. P., & Losi, S. (2018). Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish, 2018, 228424031879095. https://doi.org/10.1177/2284240318790951

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free